IN BRIEF: Crism flags contract talks, reacts to share price surge

Crism Therapeutics Corp - Pharmaceutical company headquartered in Surrey - Notes the increase in ...

Alliance News 3 July, 2024 | 6:03PM
Email Form Facebook Twitter LinkedIn RSS

Crism Therapeutics Corp - Pharmaceutical company headquartered in Surrey - Notes the increase in the share price on Wednesday, confirms that it is not aware of any specific reason for the increase. Points out the share price has fallen since admission to AIM in May. Continues to work on its stated strategy of submitting a clinical trial application in the second half of 2024 for its lead product, ChemoSeed. Also at contract stage to provide services with an early stage UK small and medium sized enterprise who are seeking to utilise Crism's drug formulation expertise. The value of that contract would be around GBP230,000.

Current stock price: 25.50 pence, more than quadrupled on Wednesday in London

12-month change: down 29%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Crism Therapeutics Corp 15.75 GBX -4.55 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures